OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)

SEATTLE, March 15, 2023 /PRNewswire/ — OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced a poster presentation at the upcoming American Association for Cancer Research Annual Meeting being…